CVS Health Corp vs Medpace Holdings Inc — how do they compare? CVS Health Corp trades at $93.62 (market cap $119.58B), while Medpace Holdings Inc trades at $609.54 (market cap $16.90B). The key difference: CVS Health Corp is far larger — about 7.1× Medpace Holdings Inc's market cap, and CVS Health Corp pays a 2.84% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| CVS | MEDP | |
|---|---|---|
Market Cap | $119.58B | $16.90B |
Sector | Health | Technology |
52-Week High | $110.60 | $620.59 |
52-Week Low | $65.51 | $393.42 |
Enterprise Value | $181.93B | $16.52B |
Dividend Yield | 2.84% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MEDP trades at $590.67, up 0.97% on the day, near its consensus price target of $599.57. The stock shows bullish momentum with a golden cross formation and strong institutional interest, while recent Q2 2026 earnings beat estimates with EPS of $4.25 versus $3.98 expected. Revenue growth remains robust, projected to rise from $2.53 billion in 2025 to $2.8 billion in 2026, supporting a premium valuation with a P/E of 35.4.
Outlook is positive given earnings consistency and raised 2026 guidance, but risks include high valuation sensitivity and a shareholder lawsuit investigation. The stock offers growth potential from a strong backlog and net book-to-bill ratio of 1.13x, though investors should monitor legal developments and competitive pressures in medical services.
Trailing returns across standard periods
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →